Open Access<i>NAT2</i> and <i>CYP1B1</i> genetic polymorphisms in patients with genital endometriosis depending on tolerability of melatonin
Author(s) -
Т. Э. Иващенко,
Иващенко Татьяна Эдуардовна,
Maria I. Yarmolinskaya,
Ярмолинская Мария Игоревна,
Saimat Sh. Tkhazaplizheva,
Тхазаплижева Саимат Шауаловна
Publication year - 2021
Publication title -
žurnalʺ akušerstva i ženskihʺ boleznej
Language(s) - English
Resource type - Journals
eISSN - 1684-0461
pISSN - 1683-9366
DOI - 10.17816/jowd51149
Subject(s) - melatonin , endometriosis , tolerability , medicine , cyp1b1 , gene polymorphism , allele , endocrinology , gene , biology , genetics , adverse effect , metabolism , cytochrome p450
BACKGROUND: Genital endometriosis is one of the most pressing problems of modern gynecology. Melatonin is a promising drug with a potentially curative effect on endometriosis.
AIM: The aim of this study was to conduct a comparative analysis of the genetic polymorphism of some genes encoding enzymes involved in melatonin metabolism.
MATERIALS AND METHODS: The genetic polymorphism in the NAT2 and CYP1B1 genes encoding enzymes involved in melatonin metabolism in patients with different tolerance to this drug was analyzed by PCR-RFLP analysis.
RESULTS: In patients with genital endometriosis, the presence of a wild-type allele (N) of the NAT2 gene was associated with poor tolerance of melatonin. The NAT2 (N / N) rapid acetylator phenotype combined with the low catalytic activity of CYP1B1 (C / C) occurred more frequently in endometriosis patients having poor melatonin tolerability compared to the group of patients who tolerated the therapy well.
CONCLUSIONS: For patients with genital endometriosis with the wild-type (N) allele of the NAT2 gene, melatonin administration is inappropriate due to numerous side effects during the drug use.